Clinical Trials Logo

Advanced Pancreatic Cancer clinical trials

View clinical trials related to Advanced Pancreatic Cancer.

Filter by:

NCT ID: NCT02124317 Active, not recruiting - Clinical trials for Advanced Pancreatic Cancer

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer

NAPSPAC
Start date: April 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) plus S-1 as first-line treatment in Chinese patients with advanced pancreatic ductal adenocarcinoma (PDA).

NCT ID: NCT02101580 Completed - Clinical trials for Advanced Pancreatic Cancer

Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer

Start date: November 17, 2014
Phase: Phase 1
Study type: Interventional

Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in subjects with Advanced Pancreatic Carcinoma.

NCT ID: NCT01885884 Active, not recruiting - Clinical trials for Advanced Pancreatic Cancer

Supportive Care Intervention-Pancreas

SCI-P
Start date: July 2013
Phase: N/A
Study type: Interventional

This is a pilot, randomized controlled trial of an embedded collaborative model of supportive care designed to improve quality of life and decrease use of unwanted healthcare services at the end of life for patients with advanced pancreatic cancer. We will enroll 30 patients who are receiving treatment at the Hillman Cancer Center for recently diagnosed, locally advanced or metastatic pancreatic adenocarcinoma, as well as their accompanying caregivers and providers. Patients will be randomized to receive either the supportive care intervention or usual care. The purpose of this study is to refine an embedded collaborative model of supportive care and to develop protocols for recruitment, randomization, and longitudinal data collection.

NCT ID: NCT01764477 Completed - Clinical trials for Pancreatic Adenocarcinoma

Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma

Start date: April 2013
Phase: Phase 1
Study type: Interventional

Laboratory studies suggest that the study drug may stop cancer cells from growing by affecting an interaction between proteins in the cells referred to as cAMP-response element-binding protein and ß-catenin. The purpose of this research study is to determine the highest safe dose of study drug that may be used when it is given together with a chemotherapy drug to patients with cancer of the pancreas.

NCT ID: NCT01303172 Completed - Clinical trials for Advanced Pancreatic Cancer

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Start date: June 2011
Phase: Phase 2
Study type: Interventional

To compare, in patients with advanced pancreatic cancer, the effects of IMM-101 in combination with gemcitabine to gemcitabine alone on safety and tolerability (including QoL), clinical signs and symptoms of disease, selected markers of tumour burden and immunological status, and disease outcome.

NCT ID: NCT01048320 Completed - Clinical trials for Advanced Pancreatic Cancer

Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer

RPGOG1
Start date: July 2006
Phase: Phase 1
Study type: Interventional

The main research objective is to work out the optimal doses of the novel combination of gemcitabine, oxaliplatin and imatinib mesylate (glivec) in patients with advanced pancreatic cancer that has progressed during or after treatment with first-line gemcitabine.

NCT ID: NCT01010945 Completed - Clinical trials for Advanced Pancreatic Cancer

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Start date: February 3, 2010
Phase: Phase 1
Study type: Interventional

This is a phase 1b study to evaluate the combination of gemcitabine and Tarceva (erlotinib) and nab-paclitaxel in patients with advanced pancreatic cancer.